of Racemic Drug Formulations: Is Stereospecific Assay Essential?

[1]  L. Benet,et al.  Chiral Bioequivalence , 2000, Clinical pharmacokinetics.

[2]  K. Midha,et al.  The impact of stereoisomerism in bioequivalence studies. , 1998, Journal of pharmaceutical sciences.

[3]  F. Jamali,et al.  Bioequivalence of Chiral Drugs , 1997, Clinical pharmacokinetics.

[4]  A. Karim.  Enantioselective Assays in Comparative Bioavailability Studies of Racemic Drug Formulations: Nice to Know or Need to Know? , 1996, Journal of clinical pharmacology.

[5]  A. Karim,et al.  Verapamil stereoisomerism: Enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both , 1995, Clinical pharmacology and therapeutics.

[6]  G. Geisslinger,et al.  Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate. , 1995, British journal of clinical pharmacology.

[7]  R. Mehvar,et al.  Input rate-dependent stereoselective pharmacokinetics. Experimental evidence in verapamil-infused isolated rat livers. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[8]  G. Amidon,et al.  The Effect of Dosage Release Formulations on the Pharmacokinetics of Propranolol Stereoisomers in Humans , 1995, Journal of clinical pharmacology.

[9]  J. Longstreth,et al.  Enantioselective Kinetics of Verapamil and Norverapamil in Isolated Perfused Rat Livers , 1994, Pharmaceutical Research.

[10]  K. Stoschitzky,et al.  Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studies. , 1994, Journal of pharmaceutical and biomedical analysis.

[11]  R. Nation.  Chirality in New Drug Development , 1994, Clinical pharmacokinetics.

[12]  F. Jamali,et al.  Etodolac Clinical Pharmacokinetics , 1994, Clinical pharmacokinetics.

[13]  F. Jamali,et al.  Stereoselective Dissolution of Propranolol Hydrochloride from Hydroxypropyl Methylcellulose Matrices , 1993, Pharmaceutical Research.

[14]  A. Ebihara,et al.  The effects of age and gender on the stereoselective pharmacokinetics of verapamil , 1993, Clinical pharmacology and therapeutics.

[15]  P. Thürmann,et al.  Plasma concentrations of S-verapamil after single doses of two different galenic formulations of racemic verapamil. , 1993, Arzneimittel-Forschung.

[16]  S. Hall,et al.  Lack of presystemic inversion of (R)‐ to (S)‐ibuprofen in humans , 1993, Clinical pharmacology and therapeutics.

[17]  Mei-ling Chen.  An Alternative Approach for Assessment of Rate of Absorption in Bioequivalence Studies , 1992, Pharmaceutical Research.

[18]  W M Nitchuk,et al.  Regulatory Requirements for Generic Chiral Drugs , 1992, Journal of clinical pharmacology.

[19]  F. Jamali.  Stereochemistry and Bioequivalence , 1992, Journal of clinical pharmacology.

[20]  Roger L. Williams,et al.  Bioequivalence of Racemic Drugs , 1992, Journal of clinical pharmacology.

[21]  J. Caldwell.  The importance of stereochemistry in drug action and disposition. , 1992, Journal of clinical pharmacology.

[22]  W. Wechter.  From Controversy to Resolution: Bioequivalency of Racemic Drugs—A Symposium on the Dynamics, Kinetics, Bioequivalency, and Analytical Aspects of Stereochemistry , 1992, Journal of clinical pharmacology.

[23]  J. Gal,et al.  Enantioselective versus non‐enantioselective assays in comparative bioavailability studies with racemic drugs , 1992, Biopharmaceutics & drug disposition.

[24]  J. Gerber,et al.  Age and gender influence the stereoselective pharmacokinetics of propranolol. , 1992, The Journal of pharmacology and experimental therapeutics.

[25]  Thomas Layloff,et al.  Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies , 1992, Pharmaceutical Research.

[26]  M. Eichelbaum,et al.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.

[27]  F. Jamali,et al.  Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. , 1992, Journal of pharmaceutical sciences.

[28]  R. Mehvar.  Stereochemical considerations in pharmacodynamic modeling of chiral drugs. , 1992, Journal of pharmaceutical sciences.

[29]  F. Jamali,et al.  Stereoselective Disposition of Etodolac Enantiomers in Synovial Fluid , 1991, Journal of clinical pharmacology.

[30]  F. Jamali,et al.  Comparative bioavailability of two flurbiprofen products: Stereospecific versus conventional approach , 1991, Biopharmaceutics & drug disposition.

[31]  W. Bussmann.  Kleine nitratdosen bereits wirksam , 1991, European Journal of Clinical Pharmacology.

[32]  W. Lindner,et al.  The effects of the stereoisomers of propafenone and diprafenone in guinea‐pig heart , 1991, British journal of pharmacology.

[33]  P. Thürmann,et al.  Pharmacodynamic Profile of Verapamil in Relation to Absolute Bioavailability: Investigations with a Conventional and a Controlled‐Release Formulation , 1991, Journal of cardiovascular pharmacology.

[34]  A. Avgerinos,et al.  Disposition of ibuprofen enantiomers following the oral administration of a novel controlled release formulation to healthy volunteers , 1991 .

[35]  L. Sansom,et al.  The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. , 1990, Biopharmaceutics & drug disposition.

[36]  D. Breimer,et al.  Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. , 1990, British journal of clinical pharmacology.

[37]  F. Jamali,et al.  The pharmacokinetics of etodolac enantiomers in the rat. Lack of pharmacokinetic interaction between enantiomers. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[38]  K. Stoschitzky,et al.  Different stereoselective effects of (R)‐ and (S)‐propafenone: Clinical pharmacologic, electrophysiologic, and radioligand binding studies , 1990, Clinical pharmacology and therapeutics.

[39]  Edmund J Lee,et al.  Chirality Clinical Pharmacokinetic and Pharmacodynamic Considerations , 1990, Clinical pharmacokinetics.

[40]  D. Birkett,et al.  RACEMATES OR ENANTIOMERS: REGULATORY APPROACHES , 1989, Clinical and experimental pharmacology & physiology.

[41]  D. Roden,et al.  Stereoselective disposition and pharmacologic activity of propafenone enantiomers. , 1989, Circulation.

[42]  R. Schilsky,et al.  Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing , 1989, Cancer.

[43]  L. Sansom,et al.  Stereoselective drug disposition: potential for misinterpretation of drug disposition data. , 1988, British journal of clinical pharmacology.

[44]  D. J. Squires,et al.  Comparative human study of ibuprofen enantiomer plasma concentrations produced by two commercially available ibuprofen tablets , 1988, Biopharmaceutics & drug disposition.

[45]  F. Jamali,et al.  Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans. , 1988, Journal of pharmaceutical sciences.

[46]  A. Russell,et al.  Stereoselective pharmacokinetics of flurbiprofen in humans and rats. , 1988, Journal of pharmaceutical sciences.

[47]  F. Jamali,et al.  Stereoselective pharmacokinetics of ketoprofen in the rat. Influence of route of administration. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[48]  I. Tamai,et al.  Stereospecific Absorption and Degradation of Cephalexin , 1988, The Journal of pharmacy and pharmacology.

[49]  W. L. Nelson,et al.  In vivo interaction of the enantiomers of disopyramide in human subjects , 1986, Journal of Pharmacokinetics and Biopharmaceutics.

[50]  M. Gibaldi,et al.  The warfarin‐sulfinpyrazone interaction: stereochemical considerations , 1986, Clinical pharmacology and therapeutics.

[51]  M. Eichelbaum,et al.  Effects of d,l‐verapamil on atrioventricular conduction in relation to its stereoselective first‐pass metabolism , 1985, Clinical pharmacology and therapeutics.

[52]  M. Eichelbaum,et al.  Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. , 1984, British journal of clinical pharmacology.

[53]  R. Norris,et al.  Propranolol disposition after acute myocardial infarction , 1984 .

[54]  J. Caldwell,et al.  The Importance of Stereochemistry in the Clinical Pharmacokinetics of the 2-Arylpropionic Acid Non-Steroidal Anti-Inflammatory Drugs , 1984, Clinical pharmacokinetics.

[55]  M. Eichelbaum,et al.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. , 1984, British journal of clinical pharmacology.

[56]  R. O'Reilly.  Ticrynafen‐racemic warfarin interaction: Hepatotoxic or stereoselective? , 1982, Clinical pharmacology and therapeutics.

[57]  J. Hermansson,et al.  Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man. , 1982, British journal of clinical pharmacology.

[58]  R. Davies,et al.  Pharmacology of enantiomers and (–) p‐OH metabolite of indacrinone , 1981, Clinical pharmacology and therapeutics.

[59]  M. Eichelbaum,et al.  The metabolism of DL-[14C]verapamil in man. , 1979, Drug metabolism and disposition: the biological fate of chemicals.

[60]  J. Morris,et al.  Active Transport of L-Dopa in the Intestine , 1973, Nature.

[61]  D. Shand,et al.  Plasma Propranolol Levels in the Quantitative Assessment of β-adrenergic Blockade in Man , 1970, British medical journal.

[62]  C. Ingold,et al.  The specification of asymmetric configuration in organic chemistry , 1956, Experientia.

[63]  G. Geisslinger,et al.  Pharmacokinetics of S(+)- and R(−)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis , 2006, European Journal of Clinical Pharmacology.

[64]  H. Brodthagen,et al.  Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker , 2004, European Journal of Clinical Pharmacology.

[65]  E. J. Ariëns.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology , 2004, European Journal of Clinical Pharmacology.

[66]  S. Higuchi,et al.  Determination of (+)- and (-)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine , 2004, European Journal of Clinical Pharmacology.

[67]  A. Evans.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs , 2004, European Journal of Clinical Pharmacology.

[68]  K. Stoschitzky,et al.  Stereoselective electrophysiological effects of propafenone in Langendorff perfused guinea pig hearts , 2004, Basic Research in Cardiology.

[69]  F. Jamali,et al.  Pharmacokinetics of Ibuprofen Enantiomers in Humans Following Oral Administration of Tablets with Different Absorption Rates , 2004, Pharmaceutical Research.

[70]  L. Lesko,et al.  Measures of Exposure versus Measures of Rate and Extent of Absorption , 2001, Clinical pharmacokinetics.

[71]  L. Sansom,et al.  Bioequivalence requirements for generic products. , 1994, Pharmacology & therapeutics.

[72]  M. Gibaldi.  Stereoselective and isozyme-selective drug interactions. , 1993, Chirality.

[73]  I. Wainer,et al.  An in vitro study of the stereoselective dissolution of (rac)-verapamil from two sustained release formulations , 1993 .

[74]  G. Tucker,et al.  Enantiomer specific pharmacokinetics. , 1990, Pharmacology & therapeutics.

[75]  S. Hall,et al.  High-performance liquid chromatographic analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine. , 1989, Journal of chromatography.

[76]  J. Paulson,et al.  Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. , 1989, British journal of clinical pharmacology.

[77]  F. Jamali,et al.  Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. , 1988, Journal of pharmaceutical sciences.

[78]  J. Caldwell,et al.  The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. , 1988, Biochemical pharmacology.